The company said, “With the Chief Executive Officer and Chief Financial Officer transition, Maravai is withdrawing and suspending revenue guidance for 2025. The new leadership team is in the midst of a comprehensive business review and forecasting process and will look to reinstate guidance once that process is complete.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai Lifesciences Announces Major Organizational Restructuring
- Maravai Lifesciences Holdings, Inc. (MRVI) Q2 Earnings Cheat Sheet
- Strategic Leadership Changes and Financial Discipline Drive Buy Rating for Maravai Lifesciences Holdings
- Maravai Lifesciences Appoints New CFO Rajesh Asarpota
- Maravai Lifesciences CFO Kevin Herde to switch roles, Rajesh Asarpota to succeed